Clinical comparison of selective and non-selective α1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses

British Journal of Urology

Volumn 80, Issue 4, 1997, Pages 606-611

  Lee, E ^a,b   Lee, C ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Selective and non selective 1A adrenoreceptor antagonist; Tamsulosin; Terazosin

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN; TERAZOSIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SINGLE BLIND PROCEDURE; SYMPTOM; SYSTOLIC BLOOD PRESSURE; URINARY TRACT OBSTRUCTION; URINE FLOW RATE; VERTIGO; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME; URINATION;

EID: 0031403135     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
2. Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannagan M, Milroy EJG. Prazosin in the treatment of prostatic obstruction: a placebo-control study. Br J Urol 1987; 60: 136-42
3. Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
4. Brawer MK, Adams G, Epstein H, the Terazosin Benign Prostatic Hyperplasia Study Group. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993; 2: 929-35
5. Roehrborn CG, Oesterling JE, Arbor A et al. Hytrin Community Assessment Trial (HYCAT): evaluation of the clinical effectiveness of terazosin versus placebo in the treatment of patients with symptomatic benign prostatic hyperplasia. J Urol 1995; 153 (suppl): 272 abstr 175
6. Chapple CR, Carter P, Christmas TJ et al. A three month double-blind placebo controlled study of doxazosin as treatment for benign prostatic bladder outflow obstruction. Br J Urol 1994; 74: 50-6
7. Jardin A, Bensadoun H, Delauche-Cavallier MC et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. Br J Urol 1994; 74: 579-84
8. Kunisawa Y, Kawabe K, Niijima T, Honda K, Takenaka T. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder and prostatic urethra. J Urol 1985; 134: 396-8
9. Yamada S, Tanaka C, Kimura R, Kawabe K. Alpha-1 adrenoreceptors in human prostate: Characterization and binding characteristics of alpha-1-antagonists. Life Sci 1994; 54: 1845-54
10. Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate 1990; 3 (Suppl): 75-84
11. Hieble JP, Caine M, Zalaznik E. In vitro characterization of the alpha-adrenoreceptors in human prostate. Eur J Pharmacol 1985; 107: 111-7
12. 1-adrenoreceptor classification: sharpening Occam's razor. Trends Pharmacol Sci 1994; 15: 167-70
13. 1-adrenoreceptor: Consensus Update. Pharmacol Rev 1995; 47: 267-70
14. Price DT, Schwinn DA, Lomasney UW et al. Identification, quantification and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-51
15. 1-adrenoreceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 1994; 21: 405-11
16. 1-adrenoreceptor subtype selectivity of tamsulosin: studies using livers from different species. Eur J Pharmacol Mol Pharmacol 1995; 289: 1-7
17. 1-adrenoreceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Arch Pharmacol 1993; 348: 385-95
18. 1-adrenoreceptors in human prostates with benign prostatic hypertrophy. Urol Res 1994; 22: 272-8
19. 1-adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol Mol Pharmacol 1995; 288: 201-7
20. 1-adrenoreceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994; 113: 723-8
21. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-12
22. Kawabe K. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 1995; 76 (Suppl 1): 63-7
23. 11c-adrenoreceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995; 76: 325-36
24. 1A-adrenoreceptor antagonist: analysis of a multinational, multicenter, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction(symptomatic BPH). Eur Urol 1996; 29: 145-54
25. 1-adrenoreceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129-44
26. Lepor H, the Tamsulosin Investigator Group. Clinical evaluation of tamsulosin, a prostate selective alpha-1c-antagonist. J Urol 1995; 153 (Suppl): 274, abstr 182
27. Lee E, Lee C, Kim Y. Shin Y. Estimation of benign prostatic hyperplasia prevalence in Korea: an epidemiological study using International Prostatic Symptom Score (IPSS) in Yonchon County. Korean J Urol 1995; 36: 1345-52
28. Homma Y, Imajo C, Kawabe K et al. Response criteria of treatments for benign prostatic hyperplasia. Int J Urol 1995; 2: 33-8